Skip Navigation



American Journal of Epidemiology Advance Access published online on September 18, 2008
American Journal of Epidemiology, doi:10.1093/aje/kwn221
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
168/9/1047    most recent
kwn221v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stolzenberg-Solomon, R. Z.
Right arrow Articles by Albanes, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stolzenberg-Solomon, R. Z.
Right arrow Articles by Albanes, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology Published by the Johns Hopkins Bloomberg School of Public Health 2008.

Original Contribution

Prediagnostic Adiponectin Concentrations and Pancreatic Cancer Risk in Male Smokers

Rachael Z. Stolzenberg-Solomon, Stephanie Weinstein, Michael Pollak, Yuzhen Tao, Philip R. Taylor, Jarmo Virtamo and Demetrius Albanes

Correspondence to Dr. Rachael Stolzenberg-Solomon, Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd., Suite 320, Bethesda, MD 20852 (e-mail: rs221z{at}nih.gov).

Received for publication December 26, 2007. Accepted for publication June 23, 2008.

Adiponectin, a hormone secreted by adipocytes, has insulin-sensitizing, antidiabetic, antiinflammatory, and antiangiogenic properties. The authors conducted a nested case-control study in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort, a cohort of male Finnish smokers aged 50–69 years at baseline, to test whether prediagnostic adiponectin concentrations are associated with pancreatic cancer. Between January 1985 and October 2004, 311 incident exocrine pancreatic cancer cases were diagnosed among cohort participants with serum samples. Controls (n = 510) were alive and free of cancer at the time the case was diagnosed and were matched to the cases by age and date of blood drawing. The authors used conditional logistic regression adjusted for smoking, blood pressure, and C-peptide level to calculate odds ratios and 95% confidence intervals for pancreatic cancer. Higher adiponectin concentrations were inversely associated with pancreatic cancer (for highest quintile (>9.8 µg/mL) vs. lowest (≤4.6 µg/mL), odds ratio = 0.65, 95% confidence interval: 0.39, 1.07; P-trend = 0.04). The inverse association was significant among cases diagnosed 5 or more years after blood collection (n = 238) (for highest quintile vs. lowest, odds ratio = 0.55, 95% confidence interval: 0.31, 0.98; P-trend = 0.03). These results support the hypothesis that higher adiponectin concentrations may be inversely associated with the development of pancreatic cancer.

adenocarcinoma; adiponectin; biological markers; case-control studies; diabetes mellitus; pancreatic neoplasms

Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention; BMI, body mass index; CI, confidence interval; OR, odds ratio


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.